Patents Assigned to Eyegene, Inc.
-
Patent number: 10918709Abstract: The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.Type: GrantFiled: October 30, 2017Date of Patent: February 16, 2021Assignee: EYEGENE INC.Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
-
Patent number: 10874733Abstract: The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.Type: GrantFiled: October 30, 2017Date of Patent: December 29, 2020Assignee: EYEGENE INC.Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
-
Patent number: 9572877Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.Type: GrantFiled: December 17, 2011Date of Patent: February 21, 2017Assignee: EYEGENE, INC.Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won II Yoo
-
Patent number: 9566323Abstract: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.Type: GrantFiled: October 20, 2009Date of Patent: February 14, 2017Assignee: Eyegene Inc.Inventors: Hong-Jin Kim, Na Gyong Lee, Yang-Je Cho, Jin-Wook Jang, Hyoung Jin Kim, Kwang Sung Kim
-
Patent number: 9290542Abstract: The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis.Type: GrantFiled: March 11, 2013Date of Patent: March 22, 2016Assignee: EYEGENE, INC.Inventors: Yang Je Cho, Jin Wook Jang, Hyeong Joon Lim
-
Patent number: 9101581Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.Type: GrantFiled: October 2, 2013Date of Patent: August 11, 2015Assignee: EYEGENE INC.Inventors: Doo-Sik Kim, Yang-Je Cho, Won-Il Yoo, Oh-Woong Kwon, Jin-Wook Jang, Hyeong-Joon Lim, Soo-Mee Kwon
-
Patent number: 8883987Abstract: The present invention relates to immune stimulating composition comprising methylated bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.Type: GrantFiled: March 24, 2006Date of Patent: November 11, 2014Assignee: Eyegene Inc.Inventors: Bo Young Ahn, Yang Je Cho, Won Il Yoo, Sung Ho Lee, Hye Ran Park, Dong Hyun Lee, Na-Gyong Lee, Doo Sik Kim
-
Publication number: 20140105868Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.Type: ApplicationFiled: October 2, 2013Publication date: April 17, 2014Applicant: EYEGENE, INC.Inventors: Doo-Sik KIM, Yang-Je CHO, Won-Il YOO, Oh-Woong KWON, Jin-Wook JANG, Hyeong-Joon LIM, Soo-Mee KWON
-
Publication number: 20130273101Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 17, 2011Publication date: October 17, 2013Applicant: EYEGENE, INC.Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won Il Yoo
-
Patent number: 8372811Abstract: Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.Type: GrantFiled: September 21, 2007Date of Patent: February 12, 2013Assignee: Eyegene, Inc.Inventors: Jin Wook Jang, Hyeong Joon Lim, Yang Je Cho, Won Il Yoo, Doo Sik Kim, Oh Woong Kwon, Kyoung Chul Ko, Kyung Sul Kim
-
Publication number: 20120100169Abstract: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.Type: ApplicationFiled: October 20, 2009Publication date: April 26, 2012Applicant: Eyegene Inc.Inventors: Hong-Jin Kim, Na Gyong Lee, Yang-Je Cho, Jin-Wook Jang, Hyoung Jin Kim, Kwang Sung Kim
-
Publication number: 20100297100Abstract: Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.Type: ApplicationFiled: September 21, 2007Publication date: November 25, 2010Applicant: Eyegene, Inc.Inventors: Jin-Wook Jang, Hyeong-Joon Lim, Yang-Je Cho, Won-Il Yoo, Doo-Sik Kim, Oh-Woong Kwon, Kyoung-Chul Ko, Kyung-Sul Kim
-
Patent number: 7507802Abstract: The present invention relates to immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysacchararides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.Type: GrantFiled: September 26, 2002Date of Patent: March 24, 2009Assignee: Eyegene, Inc.Inventors: Bo Young Ahn, Yang Je Cho, Won Il Yoo, Sung Ho Lee, Hye Ran Park, Dong Hyun Lee, Na-Gyong Lee, Doo Sik Kim
-
Publication number: 20090061465Abstract: Disclosed are composition for diagnosing a diabetes mellitus and a retinal vascular disease, a kit for diagnosing the retinal vascular disease including the protein, a gene encoding the protein, and a method for analyzing an antibody prepared by the diabetes mellitus and/or the retinal vascular disease using the same.Type: ApplicationFiled: July 6, 2005Publication date: March 5, 2009Applicant: EYEGENE INC.Inventors: Yang-Je Cho, Bo-Young Ahn, Won-Il Yoo, Oh-Woong Kwon
-
Publication number: 20080009441Abstract: This invention relates to Cell supernatant protein for inducing angiogenesis-1 secretion. The protein of the invention can be useful as therapeutic agent for angiogenesis-related diseases.Type: ApplicationFiled: March 31, 2004Publication date: January 10, 2008Applicant: EYEGENE, INC.Inventors: Yang-Je Cho, Bo-Young Ahn, Doo-Sik Kim, Won-Il Yoo
-
Publication number: 20050163806Abstract: The present invention relates to immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysacchararides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.Type: ApplicationFiled: September 26, 2002Publication date: July 28, 2005Applicants: EyeGene Inc., Daewoong Life Science InstituteInventors: Bo Ahn, Yang Cho, Won Il Yoo, Sung Lee, Hye Park, Dong Lee, Na-Gyong Lee, Doo Kim
-
Patent number: RE48023Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.Type: GrantFiled: May 18, 2016Date of Patent: June 2, 2020Assignee: EYEGENE INC.Inventors: Doo-Sik Kim, Yang-Je Cho, Won-Il Yoo, Oh-Woong Kwon, Jin-Wook Jang, Hyeong-Joon Lim, Soo-Mee Kwon